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ABSTRACT
The objective of this study was to investigate the longitudinal
relation between the insulin-like growth factor I (IGF-I)/IGF-binding
protein (IGFBP) system and cognitive function. The study population
consisted of a sample of 186 healthy participants from the population-
based Rotterdam Study, aged 55–80 yr. At baseline, we determined
fasting blood levels of free and total IGF-I, IGFBP-1, and IGFBP-3.
The 30-point Mini-Mental State Examination (MMSE) was used to
assess cognitive impairment at baseline (MMSE score of ,26; 6% of
the sample) and cognitive decline after, on the average, 1.9 yr of
follow-up (drop in MMSE score of .1 point/year; 22% of the sample).
Odds ratios (OR) and 95% confidence intervals (95% CI) were esti-
mated using logistic regression, with adjustment for age, sex, edu-
cation, body mass index, and fasting insulin levels. Total IGF-I ap-
peared to be inversely related to cognitive impairment, although not
significantly. Higher total IGF-I and the total IGF-I/IGFBP-3 ratio
were associated with less cognitive decline (OR per SD increase 5 0.65;
95% CI 5 0.44–0.95 and OR 5 0.59; 95% CI 5 0.39–0.87, respec-
tively). No relation was observed between free IGF-I and cognitive
decline (OR 5 0.99; 95% CI 5 0.68–1.44). In conclusion, in this
prospective study higher serum total IGF-I levels and higher total
IGF-I/IGFBP-3 ratios, but not higher free IGF-I levels, were associ-
ated with less cognitive decline over the following 2 yr. Circulating
total IGF-I levels may reflect an underlying biological process that
influences cognitive decline. (J Clin Endocrinol Metab 85: 4551–4555,
2000)
THERE IS A physiological decline of the GH/insulin-likegrowth factor I (IGF-I) axis with aging (1).The possibility
that the GH/IGF-I axis is involved in cognitive deficits has been
recognized for several years. Animal and in vitro studies
showed that IGF-I enhances neuronal survival and inhibits
apoptosis (1a). It exerts neurotrophic activities in the hippocam-
pus, which is involved in learning and memory (1b). Finally,
IGF-I may result in a reduction of the formation of tangles,
which is one of the hallmarks of Alzheimer’s disease (1c). Few
cross-sectional epidemiological studies have found a relation-
ship between IGF-I levels and cognitive function. In childhood
GH deficiency, a state characterized by low total IGF-I levels,
cognitive impairment has been reported (2–4). Healthy cente-
narians with a higher serum total IGF-I and total IGF-I over
IGF-binding protein-3 (IGFBP-3) ratio had less cognitive im-
pairment (5). In two other small studies of older subjects, high
serum total IGF-I levels were associated with better cognitive
performance as well (6, 7).
Until now, only the link between total IGF-I levels or the ratio
of total IGF-I to IGFBP-3 and cognitive function has been in-
vestigated. However, the amount of total IGF-I in blood is a
reflection of the sum of IGF-I bound to specific IGFBPs and free
IGF-I. The bioavailability of IGF-I to the tissues is modulated by
at least six IGFBPs and several IGFBP-proteases (8, 9). IGFBP-3
is quantitatively the most important binding protein and is
thought to function as an intravascular reservoir for IGF-I (10).
IGFBP-1 has been proposed as a regulator of IGF-I bioactivity
and might simultaneously both inhibit and potentiate IGF-I
action at different sites (11). Until recently, when IGF-I was
assayed in serum, the total extractable IGF-I was measured,
which offers only a crude estimate of biologically active IGF-I
due to the wide interindividual variation in circulating IGFBP
(12). Serum free IGF-I, analogous to sex and thyroid hormones,
is likely to be more biologically active than bound IGF-I (13).
Moreover, it has been observed that normal or even increased
levels of free IGF-I may occur with subnormal circulating total
IGF-I levels (14, 15). Consequently, it seems desirable to dis-
tinguish between free and total IGF-I levels. Recently, a well
validated method has been developed to measure free IGF-I
levels (16–18).
To our knowledge, no previous study has prospectively
investigated the association between the IGF-I/IGFBP sys-
tem and cognitive function in healthy subjects. Therefore, the
current prospective population-based study was designed to
investigate whether in healthy elderly men and women cir-
culating serum levels of total and free IGF-I as well as the
ratio of total IGF-I to IGFBP-3, as this ratio has been found
to be related to cognitive impairment in a previous study (5),
are associated with cognitive decline.
Subjects and Methods
Study population
The Rotterdam Study is a single center, prospective, population-
based study (19) designed to investigate determinants of chronic dis-
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abling diseases in the elderly. The conduct of the study was approved
by the medical ethics committee of Erasmus University, and written
consent was obtained from all participants. All residents of Ommoord,
a suburb in Rotterdam, aged 55 yr or over, including those living in
homes for the elderly, were invited to participate. The baseline exam-
inations started in May 1990 and continued until June 1993. Of the 10,275
eligible subjects, 7,983 (78%) agreed to participate. During a home visit,
trained interviewers administered a questionnaire, covering, among
other areas, socio-demographic background, medical history, and med-
ication use. This was followed by 2 clinical examinations at the research
center, including neuropsychological testing. The follow-up examina-
tion started in September 1993 and lasted until December 1994. Of the
7,215 subjects who were still alive, 6,315 (88%) agreed to participate.
Data for the present study come from an additional examination of
endocrine factors. For this examination, a random sample (n 5 219) was
taken of subjects, aged 55–80 yr, who had completed the baseline ex-
amination of the Rotterdam Study not more than 6 months previously.
Persons with a history of psychiatric or endocrine diseases, including
diabetes mellitus treated with medication, were not invited.
There were no differences in age, sex, or education between our
sample and other participants of the Rotterdam Study in the same age
range and without dementia or known diabetes mellitus. The mean
baseline Mini-Mental State Examination (MMSE) score was higher in our
sample [28.1 (sd 5 1.6) vs. 27.6 (sd 5 1.9); P 5 0.002], which was probably
the result of the selection criteria.
Blood measurements
Blood was obtained after an overnight fast at the research center
between 0800–0900 h and was allowed to coagulate for 30 min. Serum
was separated by centrifugation and was quickly frozen in liquid ni-
trogen. Free IGF-I was measured with a commercially available two-site
immunoradiometric assay (Diagnostics Systems Laboratories, Inc., Web-
ster, TX; intra- and interassay coefficients of variation (CV), 10.3% and
10.7%, respectively) (16, 17). Total IGF-I was determined by a commer-
cially available RIA (Medgenix Diagnostics, Brussels, Belgium; intra-
and interassay CV, 6.1% and 9.9%, respectively). Commercially available
immunoradiometric assays were also used for measurement of IGFBP-1
and IGFBP-3 (Diagnostics Systems Laboratories, Inc.; intra- and inter-
assay CV for IGFBP-1, 4.0% and 6.7%, respectively; for IGFBP-3, 1.8%
and 1.9%, respectively). Insulin was determined by a commercially
available RIA (Medgenix; intra- and interassay CV, 8.0% and 13.7%,
respectively). Dehydroepiandrosterone sulfate (DHEAS) was assayed
by RIA (Diagnostic Products, Los Angeles, CA; intra- and interassay CV,
5.3% and 7.0%, respectively). Serum glucose levels were determined
using a standard glucose hexokinase method.
Cognitive function
Global cognitive function was tested at both baseline and follow-up
with the Dutch version of the 30-point MMSE during the (first) visit to
the research center (20). It was administered by specially trained re-
search assistants. The MMSE includes questions on orientation to time
and place, registration, attention and calculation, recall, language, and
visual construction. This screening test was originally created for a
clinical setting (21) and is extensively used in epidemiological studies
(21). Although it tests mainly cortical functions, these are important to
daily functioning and are severely affected in dementia. If fewer than 4
individual items (of 20) were not answered by the subject, these were
rated as error (22). If a subject did not answer 4 or more individual items,
the total MMSE score was considered missing. Cognitive impairment
was defined as a score below 26 (23), and cognitive decline was con-
sidered a drop in the MMSE score of more than 1 point/yr (approxi-
mately .1 sd). The mean follow-up time between the first and second
MMSEs was 1.9 yr (sd 5 0.23).
Other measurements
Height and weight were measured wearing indoor clothes and with-
out shoes. Body mass index was defined as weight (kilograms) divided
by the square of height (meters).
Blood pressure was measured twice in the sitting position with a
random zero sphygmomanometer, and the average was used for further
analyses. Hypertension was defined as a systolic blood pressure more
than 160 mm Hg, a diastolic blood pressure more than 90 mm Hg, or the
use of antihypertensive medication. Food intake was assessed with a
semiquantitative food frequency questionnaire at baseline, which aimed
to assess habitual food intakes during the past year and included 170
food items and questions about dietary habits, supplementation, and
prescribed diets (24). This questionnaire was found to have good reli-
ability and validity (24). Education was classified into four levels: com-
pleted primary education, lower vocational or general education, inter-
mediate vocational or general education, and higher vocational training,
college, or university (UNESCO, Paris, 1976). Self-reported health status
was assessed by asking participants whether they judged the quality of
their health status as better, the same, or worse than that of their peers.
Statistical analysis
Complete information on cognitive function at baseline was available
for 186 subjects, because, due to logistic reasons and refusal, not ev-
eryone was given the MMSE. Follow-up data on cognitive decline were
available for 166 subjects. Differences in baseline characteristics accord-
ing to IGF-I levels above and below the median and according to cog-
nitive decline were tested after adjustment for age by analyses of co-
variance. Logistic regression was used to estimate odds ratio (OR) and
95% confidence intervals (CI) for the risk of cognitive impairment and
decline. The independent variables of interest were total IGF-I, free
IGF-I, IGFBP-1, IGFBP-3, and the ratio of total IGF-I to IGFBP-3. To
maximize the power, we entered the variables of interest continuously
(per sd) in the logistic model. Because they were not normally distrib-
uted, we first performed a log transformation. The choice of confound-
ing variables included in the models was based either on a statistically
significant association with the determinant and the outcome, on a
previously observed association between them, or on a theoretical re-
lationship. Confounding variables included in the main model were age,
sex, education, body mass index, and fasting insulin levels. Additionally,
we adjusted for glucose levels, hypertension, DHEAS, cigarette smoking
(former, current, or never), total energy or protein intake, and self-
reported health perception. We also investigated whether there was
effect modification by gender by including the product term as covariate
in the model. All tests were two-sided, and P , 0.05 was considered
statistically significant. Data analyses were performed using BMDP
statistical software (BMDP Statistical Software, Inc.).
Results
The mean age of the participants at baseline was 67.4 yr (sd
5 5.6). Fifty percent of the sample was female. The median
baseline MMSE score was 28 (range, 20–30), and 5.9% of the
subjects were cognitively impaired. The mean drop in
the MMSE per yr was 0.21 (sd 5 0.92); 22% showed a drop
in the MMSE score of more than 1 point/yr. There were no
differences in age, sex, serum free or total IGF-I, IGFBP-1, or
IGF-I/IGFBP-3 ratio between subjects with and those with-
out a baseline MMSE score. Compared with subjects who
attended the follow-up examination (n 5 166), those who did
not (n 5 20) were older (71.1 vs. 66.9 yr; P 5 0.002) and had
a lower median MMSE score at baseline (27 vs. 28; P 5 0.001).
There were no differences in IGF-I, IGFBP-1, or IGFBP-3
levels between these groups.
Subjects with a total IGF-I level above the median (17.8
nmol/L) were younger than those with a total IGF-I level
below the median (Table 1). Mean DHEAS, free IGF-I, and
IGFBP-3 levels were higher, whereas IGFBP-1 was lower
among participants with a high total IGF-I, after adjustment
for age. There were no significant age-adjusted differences in
the proportion of subjects with cognitive impairment or cog-
nitive decline, or in sex, total energy intake, total protein
intake, or fasting insulin levels between subjects with a total
IGF-I level above the median and those with a total IGF-I
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below the median (Table 1). Persons with cognitive decline,
i.e. a drop in the MMSE score of more than 1 point/yr from
baseline to follow-up, had a significantly lower DHEAS, total
IGF-I, and total IGF-I/IGFBP-3 level at baseline than those
without cognitive decline, after adjustment for age (Table 2).
After adjustment for age, gender, educational level, body
mass index, and fasting insulin levels, logistic regression
analyses suggested an inverse association between total
IGF-I and cognitive impairment, although this was not sig-
nificant (OR per sd increase 5 0.76; 95% CI 5 0.41–1.41), but
not between free IGF-I and cognitive impairment (OR per sd
increase 5 0.94; 95% CI 5 0.47–1.88). In the longitudinal
analyses, total IGF-I and, not surprisingly, the total IGF-I to
IGFBP-3 ratio, but not free IGF-I, were associated with a
significantly reduced risk of cognitive decline (Table 3). Per
sd increase in the natural logarithm of IGF-I, the risk of
cognitive decline was reduced by approximately 35%. Ad-
ditional adjustment for DHEAS or self-reported health status
TABLE 1. Mean characteristics according to IGF-I above and below the median
Total
population
Total IGF-I
Age-adjusted
P valuea,17.8 nmol/L
(n 5 94)b
$17.8 nmol/L
(n 5 92)b
Cognitive impairment (%) 5.8 (n 5 11) 8.6 3.1 0.87
Cognitive decline (%) 22.5 (n 5 38) 27.2 18.2 0.10
Age (yr) 67.4 (5.6) 68.2 (5.4) 66.5 (5.7) 0.05
Sex (% female) 50 (n 5 94) 55 45 0.08
Only primary education (%) 32 (n 5 60) 30 33 0.67
Body mass index (kg/m2) 26.3 (3.6) 26.3 (3.8) 26.4 (3.4) 0.72
Total energy intake (kJ/day) 8313 (2184) 8243 (2044) 8385 (2326) 0.73
Total protein intake (g/day) 82.0 (20.9) 79.9 (19.9) 84.0 (21.7) 0.32
Fasting insulin level (mU/L) 13.5 (8.0) 13.8 (8.9) 13.2 (7.1) 0.99
Random glucose level (mmol/L) 6.67 (2.15) 6.56 (2.40) 6.78 (1.89) 0.25
DHEAS (mmol/L) 3.36 (2.25) 2.89 (1.91) 3.83 (2.46) 0.002
Free IGF-I (nmol/L) 0.09 (0.05) 0.08 (0.05) 0.11 (0.05) ,0.001
IGFBP-1 (nmol/L) 0.76 (0.78) 1.01 (0.96) 0.52 (0.45) ,0.001
IGFBP-3 (nmol/L) 109.8 (26.3) 104.1 (24.1) 115.3 (27.3) 0.03
a Adjusted for age by analyses of covariance.
b SD in parentheses.
TABLE 2. Mean baseline characteristics according to cognitive decline
Cognitive declinea
Age-adjusted
P valuebAbsent
(n 5 129)b
Present
(n 5 37)b
Age (yr) 66.8 (5.5) 7.3 (6.1)c 0.77
Sex (% female) 48 53 0.41
Only primary education (%) 31 32 0.72
Body mass index (kg/m2) 26.6 (3.6) 25.7 (3.9) 0.25
Total energy intake (kJ/day) 8242 (2063) 8583 (2493) 0.33
Total protein intake (g/day) 80.8 (19.1) 84.4 (22.5) 0.25
Fasting insulin level (mU/L) 14.1 (8.5) 12.3 (5.8) 0.33
Random glucose level (mmol/L) 6.9 (2.4) 6.1 (1.1) 0.06
DHEAS (mmol/l) 3.58 (2.38) 2.68 (1.65) 0.02
Total IGF-I (nmol/L) 19.6 (7.7) 16.2 (6.8) 0.006
Free IGF-I (nmol/L) 0.093 (0.06) 0.087 (0.04) 0.50
IGFBP-1 (nmol/L) 0.74 (0.83) 0.79 (0.69) 0.62
IGFBP-3 (nmol/L) 109.4 (25.8) 113.3 (26.3) 0.39
Ratio total IGF-1/IGFBP-3 0.19 (0.08) 0.15 (0.06) 0.003
a Defined as a drop in the Mini-Mental State Examination score of more than one point per yr.
b SD in parentheses.
c Adjusted for age by analyses of covariance.
TABLE 3. Risk of cognitive decline from baseline to follow-up (n 5 37/166) per SD increase in log-transformed selected metabolic factors
SD of the natural
logarithm
Adjusted relative risk (95% confidence interval)
Basic modela 1 Adjustment for
DHEAS
1 Adjustment for
self-reported health
Free IGF-I 0.595 0.99 (0.68–1.44) 1.02 (0.70–1.50) 1.01 (0.69–1.48)
Total IGF-I 0.464 0.65 (0.44–0.95) 0.67 (0.45–0.99) 0.66 (0.45–0.97)
IGFBP-1 1.02 0.92 (0.62–1.37) 0.88 (0.59–1.31) 0.92 (0.61–1.37)
IGFBP-3 0.244 1.26 (0.84–1.89) 1.25 (0.83–1.88) 1.31 (0.87–1.99)
Total IGF-I/IGFBP-3 0.097 0.59 (0.39–0.87) 0.60 (0.40–0.91) 0.59 (0.39–0.88)
Cognitive decline was defined as a drop in the MMSE score of more than one point per yr.
a Adjusted for age, sex, education, body mass index, and fasting insulin levels.
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did not essentially alter the results (Table 3), nor did adjust-
ment for hypertension, smoking, total energy intake, total
protein intake, or baseline MMSE score (data not shown).
There was no significant interaction between IGF-I and sex.
To examine whether the relationship was nonlinear or in-
fluenced by outliers, we redid the analyses according to
tertiles of IGF-I and the total IGF-I to IGFBP-3 ratio, which
showed essentially the same results.
Discussion
In this population-based sample of elderly subjects, serum
total IGF-I and the total IGF-I to IGFBP-3 ratio were both
inversely related to cognitive decline in the next 2 yr. These
results were independent of differences in age, sex, insulin
levels, body mass index, or other major confounders. How-
ever, we found no association between free IGF-I and cog-
nitive decline.
Before interpreting our findings, some methodological is-
sues should be taken into account. The MMSE score was used
in our study to assess cognitive decline. It was not originally
created for this purpose and it may be less sensitive to small
changes in cognitive function (25). The reliability of a change
in the MMSE has been examined in patients with dementia,
and it was found that for a time interval between the MMSEs
of 1 yr or more the reliability was approximately 0.74, which
is reasonable (26). We chose a cut-off point for cognitive
decline of a drop in the MMSE score of more than 1 point/yr,
i.e. more than 1 sd (sd 5 0.92), which may not be patholog-
ically significant on an individual level, but can be of major
importance on a population level. Participants in our sample
were healthier because of the exclusion criteria, and the fol-
low-up duration was short, leading, on the average, to only
a small drop in the MMSE score. However, combined with
the small sample size, this would only impede the detection
of a significant modest association.
It could be argued that selection bias might have affected
the validity of our results. The 20 subjects in our sample
without a MMSE score at follow-up (due to death or non-
response) had a significantly lower baseline MMSE score and
were older than subjects who were not lost to follow-up, but
there were no differences in IGF-I and IGFBP levels, making
selection bias less likely.
In accordance with our findings, in two previous small
studies of elderly subjects, high circulating total IGF-I levels
were associated with better cognitive performance (6, 7).
Another study also found that a high total IGF-I to IGFBP-3
ratio was related to less cognitive impairment (5). As GH
secretion is one of the main regulators of circulating total
IGF-I and IGFBP-3 (27), our findings may suggest at first
glance that GH secretion plays an important role in age-
related cognitive decline. However, free IGF-I levels were not
associated with cognitive decline in our study. Free IGF-I
levels are probably a better indicator of GH secretion than
total IGF-I (28–31). In addition, Rollero et al. observed that
MMSE scores in elderly subjects were not related to basal GH
or GH peaks after GHRH stimulation, whereas they were
positively associated with total IGF-I levels (7). In accordance
with this, GH treatment of healthy older men (in physiolog-
ical doses, which will have elevated free IGF-I levels) did not
improve cognitive function (32). Moreover, GH replacement
of subjects with adult-onset GH deficiency was not associ-
ated with significant alterations in cognitive function (33).
Our study suggests that factors other than GH secretion are
involved in the relationship of total IGF-I and the total IGF-
I/IGFBP-3 ratio to cognitive decline.
What could then be the explanation for the observed re-
lationships of total IGF-I and the total IGF-I/IGFBP-3 ratio to
cognitive decline? There are many different conditions that
might have altered the balance between bound and free IGF-I
(8, 34). Could DHEAS be the missing link? We previously
observed in this study population that higher DHEAS levels
were associated with better cognitive function (35), whereas
Morales et al. found that DHEA administration increases
IGF-I concentrations in middle-aged and elderly (36). How-
ever, the observed associations between IGF-I and cognition
did not change after adjustment for DHEAS.
Nutrition is considered to be another major regulator of
circulating total IGF-I levels (37). Protein repletion of elderly
subjects increases serum levels of total IGF-I (38). In contrast,
protein deficiency in the diet causes suppression of circu-
lating total IGF-I (27). Elderly persons are often undernour-
ished, particularly with respect to protein (39). It has also
been found that daily dietary protein intake in elderly cor-
relates positively to cognitive performance in old age (40). In
the study by Rollero et al. (7), nutritional indexes, such as
mid-arm circumference, were positively correlated with the
MMSE scores and total IGF-I. We therefore hypothesized that
daily protein intake might be responsible for the observed
relationship between total IGF-I and cognitive decline in our
study. However, adjustment for daily dietary protein intake
did not alter the results.
Finally, total IGF-I and the ratio of total IGF-I over IGFBP-3
may be indicators of general health status, and thereby pre-
dict cognitive decline, as well as other disorders of old age.
This is in accordance with the hypothesis suggested by Blum
that the total IGF-I level signals the cell about the well-being
of the organism (27). When we adjusted for self-reported
health status, the results did not change. Self-reported health
status is, however, only a rough indicator of general health
status.
In conclusion, in this population-based study, higher se-
rum total IGF-I levels and a higher total IGF-I over IGFBP-3
ratio, but not higher free IGF-I levels, were associated with
less cognitive decline over the next 2 yr. Circulating total
IGF-I levels may reflect an unknown underlying biological
process that influences cognitive decline.
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